Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibudilast in progressive multiple sclerosis
NCT01982942Phase 2Completed
- Sponsor
- MediciNova, Inc.
- Start
- Nov 2013
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) comparing Ibudilast with Placebo (2 arms). Primary endpoints: Brain Parenchymal Fraction at 96 weeks and Percentage of Participants With Adverse Events at 96 weeks. Started Nov 2013; status: completed.
02
Drugs
ibudilast
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01982942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982942.